On March 25, the FDA approved relacorilant, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens, at least 1 of which included bevacizumab. For more information, read the FDA announcement and the Corcept Therapeutics press release.
On March 25, the FDA approved relacorilant, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens, at least 1 of which included bevacizumab.
For more information, read the FDA announcement and the Corcept Therapeutics press release.
Posted on 3/26/2026
A recent ACCC video series with three cancer programs centered on how Tumor Treating Fields (TTFields) therapy can be integrated into everyday practice without overwhelming clinical or administrative teams or the patients they care for.
